• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Polymyalgia Rheumatica: Achieving Sustained Remission

Opinion
Video

Robert Spiera, M.D., highlights the impact of sustained remission on polymyalgia rheumatica treatment, emphasizing improvements in quality of life and steroid-related effects.

This is a video synopsis/summary of a Between the Lines involving Robert Spiera, M.D., and Dana McCormick, R.Ph.

In a comprehensive conversation between Dana McCormick, R.Ph., and Robert Spiera, M.D., the significance of achieving sustained remission in polymyalgia rheumatica treatment is explored. Spiera emphasizes the clinical importance of sustained remission, linking it to improved patient outcomes. Beyond validated outcome measures, achieving sustained remission correlated with reduced fatigue, neurocognitive issues and steroid-related challenges such as myopathy. The impact extended to minimizing hyperglycemia and osteoporosis, although not measured in the trial’s small sample.

The discussion delves into the broader context of glucocorticoid dose and its impact on patients’ quality of life. Removing steroids from daily lives allowed patients to reclaim their well-being. Spiera highlights the trial’s implications for older populations, stressing that even a cumulative prednisone dose of around 1500 milligrams over a year proved clinically significant.

Regarding safety, Spiera reassures about sarilumab’s profile, noting no major safety signals. While some side effects occurred, such as neutropenia and diarrhea, they didn’t lead to study discontinuation, and adjustments were made when necessary. The study’s focus on an older population provided valuable insights without revealing unexpected safety concerns, reinforcing the potential of sarilumab in polymyalgia rheumatica treatment.

This summary was AI-generated and reviewed by Managed Healthcare Executive® staff.

Related Videos
Video 11 - "Closing Current Gaps within Fertility Benefits and Care"
Video 10 - "Shaping Fertility Coverage: Access, Costs & Medical Needs"
Video 9 - "Denial of Coverage in Fertility Care"
Video 8 - "Risks of Miscarriage and Multiple Births Associated with Fertility Care"
Video 7 - "Fertility Preservation: Egg Freezing Versus Embryo Freezing"
Video 6 - "Family Building Costs, Barriers, and Dropout Rates Associated with Fertility Care"
Video 5 - "Closing Payer Gaps and Improving Fertility Care Access"
Video 4 - "Increasing Employer Coverage and Maximizing Fertility Benefits "
Video 5 - "Relevance of NUTURE Study Findings for Patients, Payers, Providers"
Video 3 - "Improving IVF Success Rates & Utilizing AI in Fertility Health Care"
Related Content
© 2024 MJH Life Sciences

All rights reserved.